641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I

JAK1 2 inhibition with ruxolitinb potentiates ex vivo activity of epcoritamab  in primary CLL cells

PD 1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient derived xenograft models In Vivo

Integrated single cell RNA sequencing and TCR profiling identifies immune drivers of severe early toxicity in CLL patients treated with idelalisib

Ibrutinib enhances 41BB costimulated CART19 function and persistence through immune reprogramming Insights from the phase 3 ECOG ACRIN E1912 clinical Trial

CD49d expression is epigenetically regulated in chronic lymphocytic leukemia Insights from CD49d bimodal cases

Genetic analysis of B and T cell subsets from CLL patients prior to and at Richter s transformation

SAT1 a novel target of SF3B1 K700E mutant in chronic lymphocytic leukemia facilitates disease development via regulating T cell function